PRESENTATION

Q3 2023 — Results presentation

Q3 2023PDF · 21 pages12.6 MB
Slide footer goes here if required 	1

-- 1 of 21 --



-- 2 of 21 --

3

-- 3 of 21 --

4

-- 4 of 21 --

5

-- 5 of 21 --

6

-- 6 of 21 --



-- 7 of 21 --

■ ■ Operational Growth
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

-- 8 of 21 --

•
•
•
•
•
•
•
•
•
•
•
•
•
•
■ ■ Operational Growth

-- 9 of 21 --



-- 10 of 21 --



-- 11 of 21 --



-- 12 of 21 --



-- 13 of 21 --

•
–
–
–
–
–
–
–
•
–
–
–
–
–
–
–
–
•
–
•
–
–
–
–

-- 14 of 21 --



-- 15 of 21 --



-- 16 of 21 --

•
•
•
•
•
•
•
•
17

-- 17 of 21 --



-- 18 of 21 --



-- 19 of 21 --



-- 20 of 21 --

= Achieved
POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA
Sum of Program Change	Sum of Region Change	Sum of Check Change 	Sum of Program Change	Sum of Region Change	Sum of Check Change	Phase III 	Phase I/II
P US AKEEGA (niraparib/abiraterone) 	P US AKEEGA (niraparib/abiraterone) 	P CARVYKTI (ciltacabtagene autoleucel) 	P TAR-200 (RIS/gemcitabine plus cetrelimab)
P EU L1 Prostate cancer metastatic castration-
resistant (MAGNITUDE)
L1 Prostate cancer metastatic castration-
resistant (MAGNITUDE)
Relapsed Refractory multiple myeloma w/1-3
PL (CARTITUDE-4)
Non muscle invasive bladder cancer (SR-1 Early
Data)
P US TALVEY (talquetamab) 	TALVEY (talquetamab) 	P BALVERSA (erdafitinib) 	TAR-210 (RIS/erdafitinib)
P EU Relapsed Refractory Multiple Myeloma 	P EU Relapsed Refractory Multiple Myeloma 	Urothelial cancer (THOR) 	Non muscle invasive bladder cancer (Early Data)
P US ERLEADA (apalutamide) 	P US BALVERSA (erdafitinib) 	RYBREVANT (amivantamab) 	TAR-200 (RIS/gemcitabine plus cetrelimab)
P EU Tablet Reduction 	P EU Urothelial cancer (THOR) 	Frontline Non Small Cell Lung Cancer in
combination with chemotherapy (PAPILLON)
Non muscle invasive bladder cancer (SunRISe-1
Update)
TECVAYLI (teclistamab) 	P US CARVYKTI (ciltacabtagene autoleucel) 	IMBRUVICA (ibrutinib) 	P BALVERSA (erdafitinib)
P EU Relapsed Refractory Multiple Myeloma
Biweekly Dosing
P EU Relapsed Refractory multiple myeloma w/1-3
PL (CARTITUDE-4)
Relapsed Refractory patients with Mantle Cell
Lymphoma in combination with venetoclax
(SYMPATICO)
Tumor Agnostic (RAGNAR)
P US EDURANT (rilpivirine) 	amivantamab / lazertinib 	RYBREVANT (amivantamab)
P EU HIV pediatric 2-12 year old 	Non Small Cell Lung Cancer 2L (MARIPOSA-2) 	Solid Tumors (GIC2001)
OPSUMIT (macitentan) 	amivantamab / lazertinib 	P JNJ-2113
P EU Pediatric pulmonary arterial hypertension 	Non Small Cell Lung Cancer (MARIPOSA) 	Psoriasis
P US macitentan w/tadalafil FDC 	P macitentan w/tadalafil FDC 	nipocalimab
P EU Pulmonary arterial hypertension 	Pulmonary arterial hypertension (A DUE) 	Rheumatoid Arthritis
P US RYBREVANT (amivantamab) 	P SPRAVATO (esketamine) 	P nipocalimab
P EU Frontline Non Small Cell Lung Cancer in
combination with chemotherapy (PAPILLON)
Treatment Resistant Major Depressive
Disorder (ESCAPE-TRD)
Hemolytic disease of the fetus and newborn
US amivantamab / lazertinib 	TREMFYA (guselkumab)
EU Non Small Cell Lung Cancer 2L (MARIPOSA-2) 	Crohn's Disease
US amivantamab / lazertinib 	P TREMFYA (guselkumab)
Non Small Cell Lung Cancer (MARIPOSA) 	Ulcerative Colitis Monotherapy
Johnson & Johnson Innovative Medicine Pipeline – Key Events in 2023*
*This information is as of October 17, 2023 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

-- 21 of 21 --